血清EPCA-2检测在前列腺癌诊断中的临床意义  

Clinical significance of serum EPCA-2 in the diagnosis of prostate cancer

作　　者：刘松林[1] 骆磊[1] 常灿[2] 荆涛[1] 王洪[1] 马清昌 李延江[1] 

机构地区：[1]青岛大学医学院附属医院泌尿外科,山东青岛266000 [2]青岛大学医学院附属医院血液科,山东青岛266000

出　　处：《临床泌尿外科杂志》2013年第11期813-815,共3页Journal of Clinical Urology

摘　　要：目的:通过比较血清中早期前列腺癌抗原-2(EPCA-2)与前列腺特异性抗原(PSA)在前列腺癌(PCa)诊断中的特异性与敏感性,研究血清中EPCA-2对诊断PCa的临床意义。方法:收集非前列腺疾病患者20例(作为A组),BPH患者56例(作为B组),PCa患者44例(作为C组),采用酶联免疫吸附实验(ELISA)分别检测三组患者血清中EPCA-2和PSA水平,进行统计学分析。结果:①C组患者血清中EPCA-2和PSA水平分别与A组和B组患者的进行比较,均显著增高,差异有统计学意义(P<0.01)。②A组血清中EPCA-2水平均≤分界点(30μg/L)。③以30μg/L为分界点,EPCA-2对PCa诊断的特异性为92.1%,敏感性为93.2%;以4μg/L为分界点,PSA对PCa诊断的特异性为55.3%,敏感性为79.5%;PSA结合fPSA/tPSA(以0.15为分界点),对PCa诊断的特异性为78.9%,敏感性为68.2%。结论:EPCA-2作为新的诊断PCa的肿瘤标志物,较PSA具有更高的特异性和敏感性,对临床PCa的诊断具有重要意义。Objective： To investigate the clinical significance of serum early prostate cancer antigen-2 （EPCA-2） in the diagnosis of prostate cancer （PCa）by comparing the specificity and sensitivity of serum EPCA-2 with prostate specific antigen （PSA）. Method： The level of serum EPCA-2 and PSA of 20 patients without prostate disease （as group A）, 56 patients with BPH （as group B） and 44 patients with PCa （as group C） were detected respectively by ELISA. The data was analyzed statistically. Result： ①The level of serum EPCA-2 and PSA in group C increased obviously compared with those in group A and group B, which the differences denoted statistical significance （P〈0. 01）. ②The level of serum EPCA-2 in every patient of group A is less than the cutoff （30 μg/ L）.③Using a cutoff of 30μg/L, EPCA-2 had a specifieity of 92.1% and a sensitivity of 93.2% in diagnosis of prostate cancer. Using a cutoff of 4μ/L, PSA had a specificity of 55.3% and a sensitivity of 79.5 %. PSA com-bined with fPSA/tPSA （the cutoff was 0.15） had a specificity of 78.9% and a sensitivity of 68.2%. Conclusion.. As a new diagnosis biomarker, EPCA-2 showed higher specificity and sensitivity than PSA in the diagnosis of PCa, which had an important clinical significance in the diagnosis of PCa.

关 键 词：早期前列腺癌抗原-2 前列腺特异性抗原 核基质蛋白 良性前列腺增生 前列腺癌 

分 类 号：R737.25[医药卫生—肿瘤]